[1]黎 瑜,王 静.肠道微生物稳态失调对慢性肾脏病毒素的影响[J].医学信息,2025,38(03):184-187.[doi:10.3969/j.issn.1006-1959.2025.03.038]
 LI Yu,WANG Jing.Effect of Intestinal Microbial Homeostasis Disorder on Chronic Kidney Disease Toxins[J].Journal of Medical Information,2025,38(03):184-187.[doi:10.3969/j.issn.1006-1959.2025.03.038]
点击复制

肠道微生物稳态失调对慢性肾脏病毒素的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年03期
页码:
184-187
栏目:
综述
出版日期:
2025-02-01

文章信息/Info

Title:
Effect of Intestinal Microbial Homeostasis Disorder on Chronic Kidney Disease Toxins
文章编号:
1006-1959(2025)03-0184-04
作者:
黎 瑜王 静
深圳市罗湖区中医院肾病科,广东 深圳 518001
Author(s):
LI Yu WANG Jing
Department of Nephrology, Luohu Hospital of Traditional Chinese Medicine,Shenzhen 518001, Guangdong, China
关键词:
慢性肾脏病肾功能不全肠道微生物菌群尿毒症毒素
Keywords:
Chronic kidney disease Renal insufficiency Intestinal microbiota Uremic toxin
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2025.03.038
文献标志码:
A
摘要:
肠道微生物菌群在维持人体肠道内环境中的重要性逐渐得以揭示,其代谢产物直接参与慢性肾脏病尿毒症毒素积累。慢性肾脏病是由进行性毒素堆积引起贫血、容量负荷过重、电解质紊乱、矿物质和骨骼疾病和代谢性酸中毒等临床症状,其与肠道微生物群之间的相互作用越来越受关注。大量研究表明慢性肾脏病与肠道微生物稳态失衡的病理改变是通过上调产生特定有害毒素的微生物群丰度与减少产生有益产物的微生物群而互为因果。本文就肠道微生物变化及其代谢产物与慢性肾脏病尿毒症毒素之间的潜在相互作用进行综述,旨在为延缓肾功能进展提供临床治疗依据。
Abstract:
The importance of gut microbiota in maintaining the internal environment of the human gut has gradually been revealed, and its metabolites are directly involved in the accumulation of uremic toxins in chronic kidney disease. Chronic kidney disease (CKD) is a clinical symptom caused by progressive toxin accumulation, such as anemia, volume overload, electrolyte imbalance, mineral and bone diseases, and metabolic acidosis. The interaction between CKD and gut microbiota has attracted more and more attention. A large number of studies have shown that the pathological changes of chronic kidney disease and intestinal microbial homeostasis imbalance are mutually causal by up-regulating the abundance of microflora that produce specific harmful toxins and reducing the microflora that produce beneficial products. This article reviews the potential interaction between intestinal microbial changes and their metabolites and uremic toxins in chronic kidney disease, aiming to provide clinical treatment basis for delaying the progression of renal function.

参考文献/References:

[1]Ammirati AL.Chronic Kidney Disease[J].Rev Assoc Med Bras (1992),2020,66Suppl 1(Suppl 1):s03-s09.[2]Zarantonello D,Rhee CM,Kalantar-Zadeh K,et al.Novel conservative management of chronic kidney disease via dialysis-free interventions[J].Curr Opin Nephrol Hypertens,2021,30(1):97-107.[3]GBD Chronic Kidney Disease Collaboration.Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2020,395(10225):709-733.[4]Zhuang Z,Tong M,Clarke R,et al.Probability of chronic kidney disease and associated risk factors in Chinese adults: a cross-sectional study of 9 million Chinese adults in the Meinian Onehealth screening survey[J].Clin Kidney J,2022,15(12):2228-2236.[5]Kalantar-Zadeh K,Li PK,Tantisattamo E,et al.Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere[J].Patient Educ Couns,2022,105(1):243-245.[6]Schmidt TSB,Raes J,Bork P.The Human Gut Microbiome: From Association to Modulation[J].Cell,2018,172(6):1198-1215.[7]Witkowski M,Weeks TL,Hazen SL.Gut Microbiota and Cardiovascular Disease[J].Circ Res,2020,127(4):553-570.[8]Cammarota G,Ianiro G,Ahern A,et al.Gut microbiome, big data and machine learning to promote precision medicine for cancer[J].Nat Rev Gastroenterol Hepatol,2020,17(10):635-648.[9]Radjabzadeh D,Bosch JA,Uitterlinden AG,et al.Gut microbiome-wide association study of depressive symptoms[J].Nat Commun,2022,13(1):7128.[10]Vaziri ND,Wong J,Pahl M,et al.Chronic kidney disease alters intestinal microbial flora[J].Kidney Int,2013,83(2):308-315.[11]Yang T,Richards EM,Pepine CJ,et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease[J].Nat Rev Nephrol,2018,14(7):442-456.[12]Huang Y,Xin W,Xiong J,et al.The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease[J].Front Pharmacol,2022,13:837500.[13]Evenepoel P,Poesen R,Meijers B.The gut-kidney axis[J].Pediatr Nephrol,2017,32(11):2005-2014.[14]O’Donnell JA,Zheng T,Meric G,et al.The gut microbiome and hypertension[J].Nat Rev Nephrol,2023,19(3):153-167.[15]Bj?觟rkegren JLM,Lusis AJ.Atherosclerosis: Recent developments[J].Cell,2022,185(10):1630-1645.[16]Joossens M,Faust K,Gryp T,et al.Gut microbiota dynamics and uraemic toxins: one size does not fit all[J].Gut,2019,68(12):2257-2260.[17]Hobby GP,Karaduta O,Dusio GF,et al.Chronic kidney disease and the gut microbiome[J].Am J Physiol Renal Physiol,2019,316(6):F1211-F1217.[18]Karakan T,Ozkul C,Küpeli Akkol E,et al.Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders[J].Nutrients,2021,13(2):389.[19]Mishima E,Fukuda S,Mukawa C,et al.Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach[J].Kidney Int,2017,92(3):634-645.[20]Gill SK,Rossi M,Bajka B,et al.Dietary fibre in gastrointestinal health and disease[J].Nat Rev Gastroenterol Hepatol,2021,18(2):101-116.[21]Bammens B,Verbeke K,Vanrenterghem Y,et al.Evidence for impaired assimilation of protein in chronic renal failure[J].Kidney Int,2003,64(6):2196-2203.[22]Andersen K,Kesper MS,Marschner JA,et al.Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic Inflammation[J].J Am Soc Nephrol,2017,28(1):76-83.[23]Wong J,Piceno YM,DeSantis TZ,et al.Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD[J].Am J Nephrol,2014,39(3):230-237.[24]Meijers B,Evenepoel P,Anders HJ.Intestinal microbiome and fitness in kidney disease[J].Nat Rev Nephrol,2019,15(9):531-545.[25]Sun X,Liu Y.Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease[J].Int J Mol Sci,2022,23(4):2131.[26]Fr?諭k W,Kucmierz J,Szlagor M,et al.New Insights into Molecular Mechanisms of Chronic Kidney Disease[J].Biomedicines,2022,10(11):2846.[27]Poesen R,Windey K,Neven E,et al.The Influence of CKD on Colonic Microbial Metabolism[J].J Am Soc Nephrol,2016,27(5):1389-1399.[28]Stavropoulou E,Kantartzi K,Tsigalou C,et al.Focus on the Gut-Kidney Axis in Health and Disease[J].Front Med (Lausanne),2021,7:620102.[29]Tang WH,Wang Z,Levison BS,et al.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J].N Engl J Med,2013,368(17):1575-1584.[30]Caetano-Silva ME,Rund L,Hutchinson NT,et al.Inhibition of inflammatory microglia by dietary fiber and short-chain fatty acids[J].Sci Rep,2023,13(1):2819.[31]Ranganathan N,Friedman EA,Tam P,et al.Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada[J].Curr Med Res Opin,2009,25(8):1919-1930.[32]Tayebi Khosroshahi H,Vaziri ND,Abedi B,et al.Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial[J].Hemodial Int,2018,22(4):492-500.[33]Headley SA,Chapman DJ,Germain MJ,et al.The effects of 16-weeks of prebiotic supplementation and aerobic exercise training on inflammatory markers, oxidative stress, uremic toxins, and the microbiota in pre-dialysis kidney patients: a randomized controlled trial-protocol paper[J].BMC Nephrol,2020,21(1):517.

相似文献/References:

[1]谢 琴.肾小球C4d沉积在慢性肾病早期诊断及预后的价值分析[J].医学信息,2018,31(08):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
 XIE Qin.Value of Glomerular C4d Deposition in Early Diagnosis and Prognosis of Chronic Kidney Disease[J].Journal of Medical Information,2018,31(03):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
[2]韦能宝,薛志刚,毕金文.尿源性脓毒血症诊治分析[J].医学信息,2018,31(24):170.[doi:10.3969/j.issn.1006-1959.2018.24.052]
 WEI Neng-bao,XUE Zhi-gang,BI Jin-wen.Diagnosis and Treatment of Urinary Sepsis[J].Journal of Medical Information,2018,31(03):170.[doi:10.3969/j.issn.1006-1959.2018.24.052]
[3]彭琪彦.慢性肾脏病患者RBP与T淋巴细胞亚群 检测的临床意义[J].医学信息,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
 PENG Qi-yan.Clinical Significance of Detection of RBP and T Lymphocyte Subsets in Patients with Chronic Kidney Disease[J].Journal of Medical Information,2019,32(03):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
[4]崔方强.足细胞上皮间质转分化研究[J].医学信息,2019,32(22):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
 CUI Fang-qiang.Epithelial Transdifferentiation of Podocytes[J].Journal of Medical Information,2019,32(03):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
[5]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
 GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Journal of Medical Information,2019,32(03):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[6]袁 娟,赫英龙.参芎葡萄糖与前列地尔治疗慢性肾脏病的疗效比较[J].医学信息,2020,33(14):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
 YUAN Juan,HE Ying-long.Comparison of Curative Effect between Shenqiong Glucose and Alprostadil in Treating Chronic Kidney Disease[J].Journal of Medical Information,2020,33(03):163.[doi:10.3969/j.issn.1006-1959.2020.14.053]
[7]叶廷巧,赵 亮,庾 辉,等.托伐普坦治疗心力衰竭合并肾功能不全的研究[J].医学信息,2020,33(15):69.[doi:10.3969/j.issn.1006-1959.2020.15.022]
 YE Ting-qiao,ZHAO Liang,YU Hui,et al.Tolvaptan in the Treatment of Heart Failure with Renal Insufficiency[J].Journal of Medical Information,2020,33(03):69.[doi:10.3969/j.issn.1006-1959.2020.15.022]
[8]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
 NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Journal of Medical Information,2020,33(03):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
[9]王希敏.2型糖尿病并发慢性肾脏病患者外周血T淋巴细胞亚群变化与肾血管内皮功能障碍的相关 分析[J].医学信息,2021,34(23):77.[doi:10.3969/j.issn.1006-1959.2021.23.021]
 WANG Xi-min.Correlation Analysis of T Lymphocyte Subsets in Peripheral Blood with Renal Vascular Endothelial Dysfunction in Patients with Type 2 Diabetes Mellitus Complicated with Chronic Kidney Disease[J].Journal of Medical Information,2021,34(03):77.[doi:10.3969/j.issn.1006-1959.2021.23.021]
[10]刘瑞尔,严琴琴,吴 江,等.高尿酸血症对慢性肾脏病及合并症影响的研究进展[J].医学信息,2022,35(07):45.[doi:10.3969/j.issn.1006-1959.2022.07.012]
 LIU Rui-er,YAN Qin-qin,WU Jiang,et al.Research Progress of Hyperuricemia on Chronic Kidney Disease and Complications[J].Journal of Medical Information,2022,35(03):45.[doi:10.3969/j.issn.1006-1959.2022.07.012]

更新日期/Last Update: 1900-01-01